TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11226995

Group type: EXPERIMENTAL
Intervention: Oral isosmolar solution of electrolytes (ISE) administered at a volume of 4 mL/kg 3 hours before completing the fasting period
Number of subjects: 40

Group type: COMPARATOR
Intervention: Overnight fasting period for milk and solids of at least 8 hours
Number of subjects: 40
Study: 8989424

Group type: EXPERIMENTAL
Intervention: 500 micrograms of immunogen (high dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 micrograms of immunogen (low dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (alum alone)
Number of subjects: 24
Study: 8235847

Group type: EXPERIMENTAL
Intervention: In-situ posterolateral fusion (group I)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Internal stabilization with the Steffee plate and screw system (group II)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (non-instrumented posterolateral grafting)
Number of subjects: 27
Study: 3122517

Group type: EXPERIMENTAL
Intervention: Rivanol with balloon catheter and oxytocin infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rivanol with Lamicel cervical dilatator (5 mm)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rivanol with Laminaria tent (6 mm)
Number of subjects: 50
Study: 29915852

Group type: EXPERIMENTAL
Intervention: Magnesium infusion with sevoflurane anesthesia (Group S-M)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnesium infusion with desflurane anesthesia (Group D-M)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with sevoflurane anesthesia (Group S)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with desflurane anesthesia (Group D)
Number of subjects: 100
Study: 27814413

Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Number of subjects: 961

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 961
Study: 24472401

Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: new combined formulation (olmesartan medoxomil + HCTZ)
Number of subjects: 28

Group type: COMPARATOR
Intervention: co-administration of separate tablets (reference drugs)
Number of subjects: 28
Study: 22334811

Group type: EXPERIMENTAL
Intervention: Open-label fluoxetine (FLX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laboratory monitoring
Number of subjects: 60
Study: 21102998

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg (GBX)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (ZOL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 55
Study: 18203893

Group type: EXPERIMENTAL
Intervention: 5 g EPA plus high-oleic sunflower oil (HOS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: HOS only (placebo)
Number of subjects: 17
Study: 16437727

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum MIYAIRI 588 strain (CBM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amoxicillin, clarithromycin, lansoprazole (Group 1)
Number of subjects: 35
Study: 12939213

Group type: EXPERIMENTAL
Intervention: Abciximab treatment (n=1052)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Control group (no abciximab treatment, n=1030)
Number of subjects: 2082
Study: 10999156

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GMCSF) 150 mcg subcutaneously 24 hours prior to vaccination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group received standard three doses of 40 mcg hepatitis B vaccine monthly
Number of subjects: 16
Study: 8697829

Group type: EXPERIMENTAL
Intervention: Prednisone (0.75 mg/kg/d for up to 4 weeks with gradual reduction over an additional 2 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (Prednisone and Placebo)
Number of subjects: 70
Study: 1834707

Group type: EXPERIMENTAL
Intervention: Concise sealant (3M)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sealite sealant (Kerr)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Delton sealant (Johnson & Johnson)
Number of subjects: 62
Study: 7329877

Group type: EXPERIMENTAL
Intervention: Theograd
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theodur
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theolair‐SR
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rona‐slophylline
Number of subjects: 8
Study: 30321958

Group type: EXPERIMENTAL
Intervention: MOK-cast
Number of subjects: 107

Group type: COMPARATOR
Intervention: Wrap
Number of subjects: 107
Study: 28083698

Group type: EXPERIMENTAL
Intervention: LDCT-IR-FBP
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: LDCT-MBIR
Number of subjects: 151

Group type: COMPARATOR
Intervention: CECT
Number of subjects: 151
Study: 25563677

Group type: EXPERIMENTAL
Intervention: Plyometric + basketball training (PT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Basketball training (BT)
Number of subjects: 16
Study: 24247275

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) including pharmacist-led medication reconciliation, patient education, collaborative care, and voice messaging.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for clopidogrel adherence.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for statins adherence.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for ACEI/ARB adherence.
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (INT) for β-blockers adherence.
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual care (UC) group adherence.
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual care (UC) for BP and LDL-C level goals achievement.
Number of subjects: 253
Study: 22947594

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate long-acting injection (PP-LAI)
Number of subjects: 3173
Study: 19051699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15187573

Group type: EXPERIMENTAL
Intervention: Quinapril (high-tissue penetrating ACE inhibitor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalapril (low-tissue penetrating ACE inhibitor)
Number of subjects: 30
Study: 15212611

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine with lithium or valproate
Number of subjects: 0
Study: 10489384

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg orally)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8598755

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Open cholecystectomy with operative cholangiography
Number of subjects: 98
Study: 1945319

Group type: EXPERIMENTAL
Intervention: Custom programs with varying threshold determinations (2 to 15 times)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Programs that determine thresholds only twice at a given location
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Estimating global fluctuation
Number of subjects: 30
Study: 7021041

Group type: EXPERIMENTAL
Intervention: L-dopa (500 mg, orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-dopa (100 mg, orally) plus carbidopa (35 mg, orally) after pretreatment with carbidopa (50 mg every 6 h for four doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31833322

Group type: EXPERIMENTAL
Intervention: Parthenogenetic species with swimming setae
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sexual species
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Species with swimming setae
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Species without swimming setae
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Environmental variables (water temperature, pH, elevation)
Number of subjects: 111
Study: 29940864

Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Chewing Gum
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 186
Study: 27188907

Group type: EXPERIMENTAL
Intervention: High-fiber diet (HFD)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Test meal after HFD
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-fiber diet (Control)
Number of subjects: 7
Study: 24472224

Group type: COMPARATOR
Intervention: Fixed-dose combination tablet formulations of azithromycin and chloroquine (AZCQ) administered at approximately 30 mg/kg AZ and 10 mg/kg CQ once daily for 3 days in children.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two AZCQ tablets (AZ/CQ 250/155 mg per tablet) in adults.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual commercial tablets of azithromycin 500 mg and chloroquine 300 mg in adults.
Number of subjects: 0
Study: 22318278

Group type: EXPERIMENTAL
Intervention: 4CMenB at 2, 4, and 6 months with routine vaccines
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: 4CMenB at 2, 4, and 6 months without routine vaccines
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: 4CMenB with routine vaccines at 2, 3, and 4 months
Number of subjects: 1885

Group type: COMPARATOR
Intervention: Routine vaccines alone at 2, 3, and 4 months
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: 4CMenB doses administered alone
Number of subjects: 1885

Group type: COMPARATOR
Intervention: Routine vaccines given alone
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: 4CMenB and routine vaccines administered together
Number of subjects: 1885
Study: 20705156

Group type: EXPERIMENTAL
Intervention: 200 mcg misoprostol
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 400 mcg misoprostol
Number of subjects: 176
Study: 17337887

Group type: EXPERIMENTAL
Intervention: ASA + extended-release dipyridamole (DP)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Composite of stroke, myocardial infarction or vascular death
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Composite + congestive heart failure, new-onset diabetes, other designated occlusive vascular events, any death, stroke subtype by TOAST criteria, Mini Mental State Examination score
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Major hemorrhagic events
Number of subjects: 20000
Study: 15365788

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 20

Group type: COMPARATOR
Intervention: l-dopa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 20
Study: 12122551

Group type: EXPERIMENTAL
Intervention: 100 microg folic acid
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 200 microg folic acid
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 300 microg folic acid
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unfortified breakfast cereal (placebo)
Number of subjects: 70
Study: 9523035

Group type: EXPERIMENTAL
Intervention: Self-prescribed rectification of vitamins C and E at adequacy of other micronutrients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized exclusive supplementation of β-carotene ± vitamin A or E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized intervention with synchronous rectification of vitamins A+C+E+B + minerals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High vitamin E supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma values for primary prevention
Number of subjects: 0
Study: 7883280

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (vitamin C)
Number of subjects: 50
Study: 31177899

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation (led by physiotherapist)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Unsupervised rehabilitation
Number of subjects: 180
Study: 29625176

Group type: EXPERIMENTAL
Intervention: 4 sachets of Salovum®
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2 sachets of Salovum®
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (2 and 4 sachets of Salovum®)
Number of subjects: 40
Study: 26944275

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2399
Study: 25139288

Group type: EXPERIMENTAL
Intervention: Quad Pendulum (QP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Segmented Pendulum (SP)
Number of subjects: 35
Study: 21404370

Group type: EXPERIMENTAL
Intervention: fMRI data analyzed with 6- to 8-mm FWHM filters
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: fMRI data analyzed with larger filters
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: fMRI data analyzed with small and large filters
Number of subjects: 18
Study: 19132976

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16448722

Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET scan at baseline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET scan at follow-up
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 22
Study: 15485475

Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg kg(‐1) in fruit juice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg kg(‐1) in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methionine-free fruit juice (placebo)
Number of subjects: 16
Study: 11568905

Group type: EXPERIMENTAL
Intervention: Vincristine administration
Number of subjects: 11
Study: 9623632

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine (T II)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 21 g branched-chain amino acids (BCAA) (T III)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 g tyrosine (TYR) (T IV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (T I)
Number of subjects: 10
Study: 8209277

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy following surgical resection for stages I, II, and IIIA disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy for locally advanced stages IIIA and IIIB disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy for advanced stage IV disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologic response modifiers (interferons, interleukins, colony-stimulating factors, monoclonal antibodies)
Number of subjects: 0
Study: 3361457

Group type: EXPERIMENTAL
Intervention: Slab foam cushions (N = 26)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Contoured foam cushions (N = 26)
Number of subjects: 62
Study: 29956398

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Acute exercise (HIIT and MICT)
Number of subjects: 28
Study: 28590898

Group type: COMPARATOR
Intervention: Conventional hearing aids (HA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Extended-wear, deep fit hearing aids (EWHA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Hearing aids with sound generator (HA+SG)
Number of subjects: 55
Study: 26624886

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 intervention
Number of subjects: 443
Study: 24003041

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN; 5 mg/24 hours) for 7 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: None (control group, blinding under gauze dressing)
Number of subjects: 41
Study: 21410294

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg with rifampicin 600 mg/day (Study A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg with itraconazole 200 mg/day (Study B)
Number of subjects: 34
Study: 18243282

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) for 6 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI)
Number of subjects: 45
Study: 15258603

Group type: EXPERIMENTAL
Intervention: Noncontact tonometer (NCT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Ocular blood flow tonometer (OBFT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 170
Study: 12511526

Group type: EXPERIMENTAL
Intervention: 100 mg OD losartan (LOS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg OD telmisartan (TEL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg OD losartan (LOS) + 20 mg OD lisinopril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg OD telmisartan (TEL) + 20 mg OD lisinopril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg OD losartan (LOS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg BID losartan (LOS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 160 mg OD telmisartan (TEL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg BID telmisartan (TEL)
Number of subjects: 30
Study: 10886114

Group type: EXPERIMENTAL
Intervention: SFTX6c (5 pmol min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BQ‐3020 (50 pmol min‐1)
Number of subjects: 8
Study: 8927672

Group type: EXPERIMENTAL
Intervention: Sertraline (selective serotonin reuptake inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine (tricyclic antidepressant)
Number of subjects: 0
Study: 1797487

Group type: EXPERIMENTAL
Intervention: AspB10
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AspB28
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AspB9GluB27
Number of subjects: 7

Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 7
Study: 6348995

Group type: EXPERIMENTAL
Intervention: Inhalation of 200 micrograms salbutamol followed immediately by 100 micrograms beclomethasone dipropionate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inhalation of 200 micrograms salbutamol followed by 100 micrograms beclomethasone dipropionate after a timed interval of more than five minutes
Number of subjects: 25
Study: 30653843

Group type: EXPERIMENTAL
Intervention: Lutikizumab 100 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lutikizumab 25 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lutikizumab 200 mg
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lutikizumab (all doses)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lutikizumab (100 mg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lutikizumab
Number of subjects: 350
Study: 30463826

Group type: EXPERIMENTAL
Intervention: Systemic administration of methotrexate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Local administration of methotrexate
Number of subjects: 160
Study: 25944814

Group type: EXPERIMENTAL
Intervention: Retrospective reporting of visual aura symptoms
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Retrospective reporting of nonvisual aura symptoms
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Prospective recording of migraine attacks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Prospective recording of nausea
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Prospective recording of phonophobia and photophobia
Number of subjects: 267
Study: 24905427

Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET) for 12 weeks (36 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No attention control group (CG)
Number of subjects: 60
Study: 26753217

Group type: EXPERIMENTAL
Intervention: Live Patterned Sensory Enhancement (live-PSE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise instruction with live-PSE
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exercise instruction alone (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Logbook comments during live-PSE
Number of subjects: 24
Study: 20729533

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isolated left ventricular pacing
Number of subjects: 40
Study: 17679559

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium with glucose monohydrate and sorbitol via Handihaler
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium via Handihaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intal Spincaps via Spinhaler
Number of subjects: 0
Study: 15157261

Group type: EXPERIMENTAL
Intervention: 500 mL of water ingested 30 minutes before blood donation
Number of subjects: 80
Study: 11826814

Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Monitoring by family practitioners
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Patients trained in INR self-management
Number of subjects: 1200
Study: 9742716

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study: 7762198

Group type: EXPERIMENTAL
Intervention: Epicutaneous infrared laser radiation
Number of subjects: 0
Study: 2742942

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) 10 mg oral test dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) 5 mg orally twice daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reduced Haloperidol (RHAL) 10 mg oral test dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) and Reduced Haloperidol (RHAL)
Number of subjects: 12
Study: 810265

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (NP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 26
Study: 29223557

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/d plus ω‐3 fatty acids 4 g/d (ROSUMEGA group)
Number of subjects: 201

Group type: COMPARATOR
Intervention: rosuvastatin 20 mg/d (rosuvastatin group)
Number of subjects: 201
Study: 27769209

Group type: EXPERIMENTAL
Intervention: Family-based behavioral social facilitation treatment (FBSFT), 17 weekly sessions at the OOC.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment (treatment as usual, TAU), monthly counselling sessions with primary health care nurse.
Number of subjects: 120